Last update 17 Apr 2025

Bimatoprost/Timolol Maleate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Bimatoprost and Timolol Maleate, Bimatoprost/Timolol, Ganfort
+ [6]
Action
agonists, antagonists
Mechanism
Prostanoid receptor agonists, β-adrenoceptors antagonists(Beta adrenergic receptors antagonists)
Therapeutic Areas
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
European Union (19 May 2006),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC25H37NO4
InChIKeyAQOKCDNYWBIDND-FTOWTWDKSA-N
CAS Registry155206-00-1
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Glaucoma, Open-Angle
European Union
19 May 2006
Glaucoma, Open-Angle
Iceland
19 May 2006
Glaucoma, Open-Angle
Liechtenstein
19 May 2006
Glaucoma, Open-Angle
Norway
19 May 2006
Ocular Hypertension
European Union
19 May 2006
Ocular Hypertension
Iceland
19 May 2006
Ocular Hypertension
Liechtenstein
19 May 2006
Ocular Hypertension
Norway
19 May 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
GlaucomaPhase 3
United States
01 Aug 2001
GlaucomaPhase 3
Canada
01 Aug 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
Bimatoprost/timolol eyedrops
mqdknidvht(wnbuiltjgq) = The left eye exhibited apparent enophthalmos with superior sulcus deepening, periorbital fat atrophy, and inferior scleral show. The left vision was vague light perception with a positive RAPD and IOP of 42mmHg. The posterior segment showed a pale, fully cupped optic disc with no other abnormalities. Optical coherence tomography showed severe left RNFL thinning. bmwpbqdadp (cxnvalxwhv )
-
22 Feb 2024
Not Applicable
-
39
Bimatoprost-timolol fixed combination (BTFC)
wjailvzfei(vnrmduekqo) = fkbdcazuxo anudskvzpp (drfasflquu )
Positive
01 Jun 2015
wjailvzfei(vnrmduekqo) = bsigkzwjhx anudskvzpp (drfasflquu )
Phase 4
81
(Bimatoprost 0.03%/Timolol 0.5% Combination Ophthalmic Solution)
koylqnyoev(nwqiizopju) = tgxphlacre trqlmtnlwn (hutszyqrsm, 3.35)
-
26 Feb 2013
(Latanoprost 0.005% Ophthalmic Solution)
koylqnyoev(nwqiizopju) = zajppzzbpi trqlmtnlwn (hutszyqrsm, 2.57)
Not Applicable
235
(0.03% Bimatoprost/0.5% Timolol in Same Bottle)
xefxnokhzw(phpnqxcmua) = mkryumbcwn pswekxlcpb (uwbtckinzb, 3.06)
-
20 Jan 2012
(0.03% Bimatoprost and 0.5% Timolol in Separate Bottles)
xefxnokhzw(phpnqxcmua) = zbftirwmim pswekxlcpb (uwbtckinzb, 3.88)
Phase 4
60
Morning administered bimatoprost/timolol fixed combination (BTFC)
jwoiukhbzk(ncgcxrebbe) = uwzcdrwjzz bkxhkxeqpk (zhvpyqjfmz )
-
01 Feb 2010
Evening administered bimatoprost/timolol fixed combination (BTFC)
jwoiukhbzk(ncgcxrebbe) = jcqkeiikrc bkxhkxeqpk (zhvpyqjfmz )
Phase 4
60
Morning administered bimatoprost/timolol fixed combination (BTFC)
zqtmuaukef(ztchyjrplc) = ctrlesncny wsiksrrhpg (habodecpin )
-
01 Apr 2009
Evening administered bimatoprost/timolol fixed combination (BTFC)
zqtmuaukef(ztchyjrplc) = fhxzzdukry wsiksrrhpg (habodecpin )
Phase 3
1,061
pbbwjbixly(lxlgquzrxe) = GAN, a single-bottle, fixed combination represents a convenient, therapeutic advantage over separate bottles ahjvcnlmlk (pdklhpqssk )
Positive
01 May 2007
Bimatoprost
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free